OCUGEN, INC. Expense Breakdown
No Expense Breakdown for OCGN on this site yet.
- 2026-06-30: Reportable $7.24M.
- 2025-06-30: Reportable $6.77M.
Source checked: the stored Expense Breakdown page for OCGN.
Expenses by product
General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $7.24M |
| 2025-06-30 | $6.77M |
Operating expenses: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $17.93M |
| 2025-06-30 | $15.17M |
Research and development: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $10.69M |
| 2025-06-30 | $8.40M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |